Literature DB >> 15003884

Hexadecylphosphocholine interaction with lipid monolayers.

Michaëlle Rakotomanga1, Philippe M Loiseau, Michèle Saint-Pierre-Chazalet.   

Abstract

The phospholipid analogue miltefosine or hexadecylphosphocholine (HePC) is a drug of high interest in the treatment for fatal visceral leishmaniasis (VL) due to Leishmania donovani particularly because of its activity by oral route. In this study, the interaction of HePC with a monolayer of beta-palmitoyl-gamma-oleyl-phosphatidylcholine (POPC) as membrane model or sterol (ergosterol or cholesterol) was investigated. At a constant pressure of 25 mN/m, the adsorption kinetics of HePC into the monolayers showed that HePC molecules are inserted into the monolayer of lipids as monomers until the critical micellar concentration (CMC). At HePC concentrations superior to the CMC, the micelles of HePC are deployed at the interface as groups of monomers into the POPC or sterol monolayer. The study of mixture of HePC/(POPC or sterol), spread at the air-water interface, shows that a simple miscibility between HePC and POPC is observed, whereas a high condensation appears between HePC and sterols showing a high affinity between HePC and sterols. In addition, HePC does not act as detergent disturbing membrane integrity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15003884     DOI: 10.1016/j.bbamem.2004.01.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  18 in total

1.  In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.

Authors:  Karin Seifert; Simon L Croft
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  In vitro susceptibility of field isolates of Leishmania donovani to Miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity.

Authors:  Dhiraj Kumar; Arpita Kulshrestha; Ruchi Singh; Poonam Salotra
Journal:  Antimicrob Agents Chemother       Date:  2008-11-17       Impact factor: 5.191

3.  Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

Authors:  M Rakotomanga; S Blanc; K Gaudin; P Chaminade; P M Loiseau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

4.  Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro.

Authors:  Cécile Ménez; Marion Buyse; Madeleine Besnard; Robert Farinotti; Philippe M Loiseau; Gillian Barratt
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

5.  Protein- and lipid-reactive agents alter outer hair cell lateral membrane motor charge movement.

Authors:  J Santos-Sacchi; M Wu
Journal:  J Membr Biol       Date:  2004-07-15       Impact factor: 1.843

6.  Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.

Authors:  M Rakotomanga; M Saint-Pierre-Chazalet; P M Loiseau
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

7.  Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.

Authors:  José M Jiménez-López; Pablo Ríos-Marco; Carmen Marco; Josefa L Segovia; María P Carrasco
Journal:  Lipids Health Dis       Date:  2010-03-25       Impact factor: 3.876

8.  Testing the hypothesis that amphiphilic antineoplastic lipid analogues act through reduction of membrane curvature elastic stress.

Authors:  Marcus Dymond; George Attard; Anthony D Postle
Journal:  J R Soc Interface       Date:  2008-11-06       Impact factor: 4.118

9.  Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.

Authors:  Thomas P C Dorlo; Alwin D R Huitema; Jos H Beijnen; Peter J de Vries
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

10.  Lysolipid containing liposomes for transendothelial drug delivery.

Authors:  Tilen Koklic; Janez Trancar
Journal:  BMC Res Notes       Date:  2012-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.